ALT Stock Alert: Altimmune Pops on Weight-Loss Drug Findings

Altimmune (NASDAQ:ALT) stock is one of the top trending tickers this morning, with shares up about 28% as of this writing. This surge comes after the company released results from a 48-week study of pemvidutide, the firm’s GLP-1 weight-loss drug.According to Altimmmune, the drug cut less of patients’ lean mass than competing treatments.The Data on Altimmune’s Weight-Loss DrugIn the Phase 2 trial involving 391 participants, just 21.9% of the weight patients lost involved their lean mass. Per the company, the ...